Premium
The crossover of bisphosphonates to cancer therapy
Author(s) -
Sun Merry,
Iqbal Jameel,
Singh Sukhjeet,
Sun Li,
Zaidi Mone
Publication year - 2010
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05812.x
Subject(s) - medicine , bone resorption , rheumatoid arthritis , cancer , osteoporosis , adjuvant therapy , oncology , cancer research
Bisphosphonates form a class of drugs commonly used to treat disorders of osteoclastic bone resorption, including osteoporosis, Paget's disease of the bone, rheumatoid arthritis, and bone metastases. Although long established as the therapy of choice to treat such disorders, bisphosphonates’ potential in treating cancer is garnering interest. Bisphosphonates have been demonstrated to inhibit tumor growth and metastasis, induce apoptosis in tumor cells, and encourage immune reactions against tumor cells. Current applications of bisphosphonates in cancer treatment include their use to treat skeletal metastases and as an adjuvant to endocrine therapy. This review explores bisphosphonates’ current clinical utility and potential as a crossover cancer therapy.